Guerbet Reports 9% Revenue Growth and Improved Profitability for 2024

Guerbet, a global specialist in contrast agents and solutions for medical imaging, has released its financial results for the fiscal year 2024. The company reported total revenue of €841.1 million, marking a 9.0% growth on a constant exchange rate (CER) and like-for-like basis. This performance represents an acceleration compared to the previous year and reflects strong momentum across key geographic regions.

Geographically, the Americas region saw a substantial 20.5% revenue increase, while Asia grew by 10.1%. The EMEA region achieved 8.8% growth, excluding France, where a restructuring of contrast agent supply chains led to an 11.8% decrease. Within its business segments, Diagnostic Imaging revenue grew by 9.0%, and Interventional Imaging sales surpassed €100 million for the first time.

Profitability saw a notable improvement. The restated EBITDA margin reached 14.9%, up from 13.1% in the previous year. Operating income increased by 28.2% to €49.6 million. Net income for the year was €13.5 million, a decrease from €22.2 million in 2023, primarily due to increased financial expenses driven by rising interest rates and foreign exchange losses.

Guerbet has also outlined its targets for 2025, expecting a restated EBITDA margin exceeding 15%, with revenue growth projected at 3-5% and a positive free cash flow. The company plans to focus on strengthening its core strategic pillars: Diagnostic Imaging, Interventional Imaging, and specialized solutions.

The company's balance sheet shows an increase in equity to €394 million and a stronger financial leverage ratio of 2.9. Free cash flow was slightly negative at -€9.1 million but showed significant improvement compared to the prior year. The Board of Directors will propose no dividend payout for the fiscal year 2024 at the upcoming Annual General Meeting.